Barry Callebaut’s shares rose 9.0% after the earnings release, with investors likely responding to a return to volume growth: volumes were up 5.7% in both Q3 and Q4, and H2 growth in priority markets reached 7%. The picture is mixed, however: full-year volume fell 0.7% and recurring EBIT declined 14.1% in constant currency.
Barry Callebaut delivered a challenging first half, impacted by volume declines and operational disruptions, but has begun laying the groundwork for recovery through strategic refocus and cost savings.
Barry Callebaut's fiscal year 2024-2025 demonstrated resilience amidst market volatility, achieving a significant reduction in net leverage while returning to strong cash generation and profitability.